{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T20:51:22Z","timestamp":1790455882282,"version":"4.1.0"},"reference-count":11,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2019,4,8]],"date-time":"2019-04-08T00:00:00Z","timestamp":1554681600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2020,1]]},"abstract":"<jats:p>Cancer treatment has changed dramatically with the development of oral targeted therapies. Pazopanib, an oral VEGF tyrosine kinase inhibitor, is currently approved for advanced renal cell carcinoma, advanced soft tissue sarcoma, and is being studied for various tumor types. Due to the potential of increased exposure to pazopanib when crushed, pazopanib should be given as an intact whole tablet. Thus, in patients with difficulty swallowing medications or feeding tubes, pazopanib is usually not considered to be an option. Here, we describe two cases which show the administration of crushed pazopanib was feasible and had apparent clinical activity.<\/jats:p>","DOI":"10.1177\/1078155219841108","type":"journal-article","created":{"date-parts":[[2019,4,8]],"date-time":"2019-04-08T21:55:36Z","timestamp":1554760536000},"page":"232-235","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":6,"title":["Clinical outcomes and toxicities of pazopanib administered orally in crushed form: Case reports and review of the literature"],"prefix":"10.1177","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6929-7496","authenticated-orcid":false,"given":"Jill","family":"Stein","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Care, The University of Iowa Hospitals and Clinics, Iowa City, IA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Milhem","sequence":"additional","affiliation":[{"name":"Division of Hematology, Oncology, and Blood and Marrow Transplantation, University of Iowa Holden Comprehensive Cancer Center, Iowa City, IA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Vaena","sequence":"additional","affiliation":[{"name":"Division of Hematology, Oncology, and Blood and Marrow Transplantation, University of Iowa Holden Comprehensive Cancer Center, Iowa City, IA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2019,4,8]]},"reference":[{"key":"bibr1-1078155219841108","volume-title":"Votrient (package insert)","author":"Novartis","year":"2017"},{"key":"bibr2-1078155219841108","unstructured":"Committee for Medicinal Products for Human Use (CHMP), European Medicines Agency. Pazopanib summary of product characteristics, www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_Product_Information\/human\/001141\/WC500094272.pdf (2013, accessed 14 December 2018)."},{"key":"bibr3-1078155219841108","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-011-9725-2"},{"key":"bibr4-1078155219841108","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-011-1798-2"},{"key":"bibr5-1078155219841108","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp130581"},{"key":"bibr6-1078155219841108","volume-title":"Lenvima (package insert)","author":"Eisai Inc","year":"2018"},{"key":"bibr7-1078155219841108","volume-title":"Afinitor (personal communication)","author":"Novartis","year":"2018"},{"key":"bibr8-1078155219841108","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2010.199"},{"key":"bibr9-1078155219841108","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.47.0914"},{"key":"bibr10-1078155219841108","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-2652"},{"key":"bibr11-1078155219841108","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2014.503"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155219841108","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1078155219841108","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155219841108","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:21:02Z","timestamp":1777688462000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1078155219841108"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,8]]},"references-count":11,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["10.1177\/1078155219841108"],"URL":"https:\/\/doi.org\/10.1177\/1078155219841108","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,8]]}}}